

13th August, 2025

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, C-1,
Block- G, Bandra – Kurla Complex,
Bandra (East), Mumbai – 400051
Symbol: AAKAAR

Dear Sir/ Madam,

Ref.: Disclosure under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (“SEBI Regulations”)

Pursuant to Regulation 30 read with Schedule III of SEBI [Listing Obligations and Disclosure Requirements], Regulations 2015, we hereby submit the details as required under Para B, Clause 2(a) of Part A of Schedule III of the said Regulations read with the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. This disclosure has been approved by our Board of Directors in their meeting held on 13.08.2025, at 6.30 p.m. [concluded at 7.15 p.m.]

The above details required under Regulation 30 of SEBI Listing regulations are provided in Annexure I, II and III respectively.

Thanking you,

Yours truly,
For Aakaar Medical Technologies Ltd.

Anoopkumar V. Pillai
Company Secretary & Compliance Officer

Encl: as above.

Annexure I

1	Name of the entity(ies) with whom agreement/JV is signed	Hugel Inc., Republic of Korea
2	Area of Agreement/ JV	Exclusive sales and marketing agreement
3	Domestic/ International	International
4	Share exchange ratio/JV ratio	Not applicable
5	Scope of Business operation of agreement/ JV	Exclusive distribution agreement for Letybo, the US FDA–approved New Botulinum Toxin, manufactured in Republic of Korea,
6	Details of consideration paid/ received in agreement/ JV	There is no upfront payment involved in this agreement.
7	Significant terms and conditions of agreement/JV in brief	<ul style="list-style-type: none"> Under this agreement, the company has exclusive rights in India to market and sell Letybo in India as per commercial terms agreed between parties. The company expects meaningful revenue contribution from this agreement during the tenure of this agreement. The existing supplier [competitor of Hugel Inc.] will need to be terminated. In view of the confidentiality clause in the agreement, we are not permitted to share quantitative and other information pertaining to the agreement.
8	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	No
9	Size of the entity(ies)	Not applicable
10	Rationale and benefit expected	Introducing a US FDA–approved, Korean-manufactured neuromodulator is a milestone for India’s aesthetics landscape. This launch raises the bar on quality and access, while giving clinics a strong alternative to Botox®
11	Any other information relevant to be shared	Pursuant to the terms of the above agreement the company has terminated the agreement with Medytox Inc. which is a competitor to Hugel Inc. for sale of SIAX products.

Annexure II

1	Name of the entity(ies) with whom agreement/JV is signed	VM Corporation SRLS (Italy)
2	Area of Agreement/ JV	Exclusive Distribution Agreement
3	Domestic/ International	International
4	Share exchange ratio/-JV ratio	Not applicable
5	Scope of Business operation of agreement/ JV	Exclusive Distribution agreement for VM EXO Signal Hair – advanced hair restoration with synthetic exosomes, PDRN, and plant stem cells. V-Tech System – plant-based exosome treatments for skin rejuvenation. Exo V Slim – body contouring with synthetic exosomes and biomimetic peptides.
6	Details of consideration paid/ received in agreement/ JV	There is no upfront payment involved in this agreement.
7	Significant terms and conditions of agreement/-JV in brief	<ul style="list-style-type: none"> Under this agreement, the company has exclusive rights in India to market and sell in India as per commercial terms agreed between parties viz. VM EXO Signal Hair, V-Tech System, Exo V Slim The company expects meaningful revenue contribution from this agreement during the tenure of this agreement. Rights and obligations of each party has been crystallized in the agreement. In view of the confidentiality clause in the agreement, we are not permitted to share more details pertaining to the agreement.
8	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	No
9	Size of the entity(ies)	NA
10	Rationale and benefit expected	VM Corporation is renowned for blending synthetic and plant-derived

		<p>exosomes with cutting-edge actives like PDRN and biomimetic peptides—pioneering the next generation of regenerative aesthetic science.</p> <p>This arrangement is expected to provide Indian customers with Advanced hair restoration therapy combining synthetic exosomes, Plant-based exosome platform for skin rejuvenation and dermal health optimization, Innovative body contouring solution powered by synthetic exosomes and biomimetic peptides.</p>
--	--	--

Annexure III

1	Name of the entity(ies) with whom agreement/JV is signed	Invex Health Pvt.Ltd. India
2	Area of Agreement/ JV	Exclusive Marketing & Distribution Agreement
3	Domestic/ International	Domestic
4	Share exchange ratio/-JV ratio	NA
5	Scope of Business operation of agreement/ JV	Marketing and Distribution rights of Tinefcon®, the world's first TNF- α down regulator and IL-12/23 down regulator, developed for the management of Psoriasis.
6	Details of consideration paid/ received in agreement/ JV	NA
7	Significant terms and conditions of agreement/-JV in brief	<ul style="list-style-type: none"> Under this agreement the company has exclusive right to distribute Tinefcon in India. The company expects meaningful revenue contribution from this agreement during the tenure of this agreement. Rights and obligations of each party has been crystallized in the agreement. In view of the confidentiality clause in the agreement, we are not permitted to share more details pertaining to the agreement.
8	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
9	Size of the entity(ies)	Not applicable
10	Rationale and benefit expected	Tinefcon® has undergone Phase 2 and Phase 4 clinical trials involving over 400 patients. The therapy distinguishes itself from conventional Psoriasis management options through its favourable safety profile, with notably lower risks of hepatotoxicity and immunosuppression, enabling long-

		<p>term use in a broader patient base.</p> <p>Originally researched and developed by Piramal Healthcare Limited, Tinefcon® was clinically validated for its safety and efficacy through extensive programs, before Piramal sold global rights to Invex Healthcare. Invex now markets Tinefcon® internationally, while Aakaar Medical Technologies will handle marketing, sales, and doctor-led distribution exclusively in India.</p>
--	--	---